Key MessageAfter a median follow-up of 62.6 months, median overall survival in patients with *ROS1*-rearranged advanced NSCLC receiving crizotinib was 51.4 months, the longest observed to date with an *ROS1*-targeted therapy. These findings serve as a new benchmark for overall survival in patients with advanced *ROS1*-rearranged non-small-cell lung cancer and continue to support the use of crizotinib in the treatment of such patients.

Introduction
============

*ROS1* rearrangements occur in 1% to 2% of patients with non-small-cell lung cancer (NSCLC) \[[@mdz131-B1], [@mdz131-B2]\]. Chromosomal rearrangements activate *ROS1* in NSCLC, resulting in the expression of ROS1 fusion kinases that promote cellular transformation \[[@mdz131-B2], [@mdz131-B3]\].

Crizotinib is an oral tyrosine kinase inhibitor (TKI) that targets the ALK, ROS1, and MET receptor tyrosine kinases \[[@mdz131-B2], [@mdz131-B4]\]. PROFILE 1001 (ClinicalTrials.gov identifier: NCT00585195) enrolled patients with advanced NSCLC harboring *ROS1* rearrangements in a recommended phase II dose (RP2D) expansion cohort of the study between October 2010 and September 2013. Initial results from 50 patients enrolled showed an objective response rate (ORR) of 72%, with 3 complete responses (CR) and 33 partial responses (PR), median duration of response (DOR) of 17.6 months, and median progression-free survival (PFS) of 19.2 months \[[@mdz131-B5]\]. These findings showed that targeting ROS1 was an effective treatment strategy in patients with *ROS1*-rearranged NSCLC. Crizotinib received approval in the United States and the European Union for the treatment of patients with ROS1-positive advanced NSCLC in March and August 2016, respectively, and is now approved for this indication in 70 countries worldwide.

Here, we report updated antitumor activity, overall survival (OS), and safety data (additional 46.2-month follow-up for a median of follow-up period of 62.6 months in total) from 53 patients with *ROS1*-rearranged advanced NSCLC to evaluate the long-term impact of crizotinib on this molecular subset of patients.

Methods
=======

Study population and eligibility
--------------------------------

Patients aged ≥18 years with locally advanced or metastatic, histologically confirmed NSCLC positive for *ROS1* rearrangement were eligible for enrollment. Fifty-three patients were included in this analysis, including 50 patients in the ROS1-positive NSCLC expansion cohort \[[@mdz131-B5]\] and 3 patients in an ALK-negative NSCLC cohort who were retrospectively determined to be positive for *ROS1* rearrangement. Disease had to be measurable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 (or by RECIST v1.1 for the three patients in the ALK-negative NSCLC cohort). Patients were also required to have an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0--1. Those with an ECOG PS of 2 could be enrolled into the study upon agreement between the investigator and sponsor.

Study design and treatment
--------------------------

Eligible patients were enrolled in an ongoing phase I, open-label study of crizotinib, which included an initial dose-escalation phase followed by an expansion phase in which the RP2D was evaluated in molecularly defined patient cohorts. We present updated data for this population (data cut-off: 30 June 2018).

The study design has been previously described \[[@mdz131-B5]\]. The protocol was approved by institutional review boards or independent ethics committees at each site and complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws. All patients provided written informed consent.

FISH or reverse transcriptase--polymerase chain reaction (RT-PCR) testing was carried out at local laboratories (all) or at a central laboratory (two patients in the ALK-negative NSCLC cohort). Patients were considered positive for *ROS1* rearrangement by FISH if \>15% of nuclei had evidence of gene rearrangement, as previously described \[[@mdz131-B5]\]. Tumor tissue or nucleic acid was available in 30 patients to determine the ROS1 fusion partner (data analyzed and provided by Massachusetts General Hospital). Targeted next-generation sequencing (*n* = 27) and RT-PCR (*n* = 3) were used to detect ROS1 fusion transcripts, as described previously \[[@mdz131-B5]\].

Crizotinib was to be administered orally at 250 mg twice daily in continuous 28-day cycles (or 21-day cycles for the three patients in the ALK-negative NSCLC cohort), until RECIST-defined disease progression or clinical deterioration, unacceptable toxicity effects, study withdrawal or death. Patients with RECIST-defined disease progression could continue crizotinib treatment at the investigator's discretion and with approval from the sponsor.

Study end points and assessments
--------------------------------

Patients underwent baseline tumor imaging with computed tomography or magnetic resonance imaging (chest, abdomen, and pelvis). Brain/bone scans were obtained if disease at these sites was suspected. Tumor assessments were carried out every two cycles (i.e. every 8 weeks for the 50 patients in the ROS1-positive NSCLC cohort and every 6 weeks for the three patients in the ALK-negative NSCLC cohort) until RECIST-defined disease progression. Once a patient had completed 15 cycles, tumor assessments could be carried out every 4 cycles; after completion of 24 cycles (35 cycles in the ALK-negative NSCLC cohort), tumor assessments could be carried out every 6 cycles (8 cycles in the ALK-negative NSCLC cohort). After treatment discontinuation, patients were contacted every ≤3 months to collect updated survival information until 2 years after the last dose of the last patient (until at least 1 year after the last dose of the patient in the ALK-negative NSCLC cohort). Best overall response was derived from investigator assessment using RECIST v1.0 (or RECIST v1.1 for the 3 patients in the ALK-negative NSCLC cohort). ORR was based on the proportion of patients with a best overall response of confirmed CR or PR. Other end points were DOR, time to first tumor response, PFS, OS, and probability of survival at 6, 12, 24, 36, and 48 months.

Adverse events (AEs) were evaluated from the time of the first dose until 28 days following the last dose and were classified and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0.

Statistical analysis
--------------------

All patients who received at least one dose of crizotinib were included in the analyses of PFS, OS, and safety. Response-evaluable patients were defined as all patients in the safety population who had an adequate baseline disease assessment and a minimum of one postbaseline disease assessment at least 6 weeks from the first dose or who withdrew from the study or had disease progression or death at any time during the study.

Confidence intervals (CIs) for the ORR were estimated using the exact binomial method based on the F-distribution. Time-to-event data were analyzed using the Kaplan--Meier method to estimate median event times, with two-sided 95% CIs generated using the Brookmeyer--Crowley method. All analyses were carried out with SAS statistical software, v9.2 or later (SAS Institute, Inc., Cary, NC).

Results
=======

Fifty-three patients with *ROS1*-rearranged advanced NSCLC were enrolled in a RP2D expansion phase of PROFILE 1001. Fifty-one of 53 patients (96%) were confirmed to have *ROS1* rearrangements by FISH. The remaining two patients were confirmed to have *ROS1* rearrangements by RT-PCR. Patient demographics and baseline disease characteristics are described in Table [1](#mdz131-T1){ref-type="table"}. Most patients (87%) had received at least one prior systemic treatment of advanced disease, and 23% of patients had received three or more prior treatments (Table [1](#mdz131-T1){ref-type="table"}).

###### 

Demographics and baseline characteristics

  Characteristics                                                       *ROS1*-rearranged NSCLC (*N* = 53)
  --------------------------------------------------------------------- ------------------------------------
  Sex, *n* (%)                                                          
   Male                                                                 23 (43)
   Female                                                               30 (57)
  Age, years, *n* (%)                                                   
   \<65                                                                 38 (72)
   ≥65                                                                  15 (28)
   Median (range)                                                       55 (25--81)
  Race, *n* (%)                                                         
   White                                                                30 (57)
   Asian                                                                21 (40)
   Black                                                                2 (4)
  ECOG performance status, *n* (%)[^a^](#tblfn1){ref-type="table-fn"}   
   0                                                                    23 (43)
   1                                                                    29 (55)
  Smoking history, *n* (%)                                              
   Never                                                                40 (75)
   Former                                                               13 (25)
  Histological classification, *n* (%)                                  
   Adenocarcinoma                                                       51 (96)
   Squamous cell carcinoma                                              1 (2)
   Other                                                                1 (2)
  Number of prior advanced/metastatic regimens, *n* (%)                 
   0                                                                    7 (13)
   1                                                                    22 (42)
   2                                                                    12 (23)
   ≥3                                                                   12 (23)
   Median (range)[^b^](#tblfn2){ref-type="table-fn"}                    2 (1--6)

One patient (1.9%) had an ECOG performance status of 2 at baseline.

Based on patients who received ≥1 prior advanced/metastatic regimen.

ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small-cell lung cancer.

Antitumor activity
------------------

Consistent with initial results of PROFILE 1001 \[[@mdz131-B5]\], almost all evaluable patients had some degree of tumor shrinkage during the study ([supplementary Figure S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). The ORR was 72% (95% CI, 58% to 83%), with 6 CR and 32 PR (Table [2](#mdz131-T2){ref-type="table"}). Responses were rapid with a median time to first tumor response of 7.9 weeks, corresponding to the approximate time of the first on-treatment tumor scan. Responses were also durable (median DOR 24.7 months; 95% CI, 15.2--45.3). ORRs were comparable across different subgroups defined by demographic and disease baseline characteristics ([supplementary Table S1](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online). At the time of data cutoff, 36 of 53 patients (68%) had experienced disease progression or had died. The median PFS was 19.3 months (95% CI, 15.2--39.1) ([supplementary Figure S2](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

###### 

Antitumor activity end points

  End points                                                                                                              *ROS1*-rearranged NSCLC (*N* = 53)
  ----------------------------------------------------------------------------------------------------------------------- ------------------------------------
  ORR, % (95% CI)[^a^](#tblfn4){ref-type="table-fn"}                                                                      72 (58--83)
   CR, *n* (%)                                                                                                            6 (11)
   PR, *n* (%)                                                                                                            32 (60)
   SD (≥6 weeks), *n* (%)                                                                                                 10 (19)
   PD, *n* (%)                                                                                                            3 (6)
   Not evaluated[^b^](#tblfn5){ref-type="table-fn"}                                                                       2 (4)
  Median time to first tumor response, weeks (range)[^c^](#tblfn6){ref-type="table-fn"}                                   7.9 (4.3--103.6)
  Median duration of response, months (95% CI)[^d^](#tblfn7){ref-type="table-fn"}^,^[^e^](#tblfn8){ref-type="table-fn"}   24.7 (15.2--45.3)
  Median PFS, months (95% CI)[^d^](#tblfn7){ref-type="table-fn"}^,^[^f^](#tblfn9){ref-type="table-fn"}                    19.3 (15.2--39.1)

Using the exact binomial method based on F-distribution.

Responses could not be evaluated in two patients because of early death or indeterminate response.

Time to response was calculated from the date of the first dose of study drug to the date of the first documentation of PR or CR.

Estimated using the Kaplan--Meier method.

Duration of response was calculated from the date of the first documentation of PR or CR to the date of RECIST-defined progression or death.

PFS was calculated from the date of the first dose of study drug to the first documentation of objective tumor progression or death, whichever occurred first.

CI, confidence interval; CR, complete response; NSCLC, non-small-cell lung cancer; ORR, objective response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.

A total of 26 (49%) deaths occurred (median follow-up period of 62.6 months); of the remaining 27 (51%) patients, 14 (26%) remained in follow-up at data cutoff. Median OS was 51.4 months \[95% CI, 29.3 to not reached (NR)\] (Figure [1](#mdz131-F1){ref-type="fig"} and Table [3](#mdz131-T3){ref-type="table"}), and the probabilities of survival at 6, 12, 24, 36, and 48 months were 91%, 79%, 67%, 53%, and 51%, respectively.

![Overall survival. Shown is the Kaplan--Meier curve estimating overall survival (OS) among the 53 ROS1-positive NSCLC patients treated with crizotinib in PROFILE 1001. After a median follow-up of 62.6 months, median OS was 51.4 months. Vertical lines on the curve indicate censoring of data.](mdz131f1){#mdz131-F1}

###### 

Summary of overall survival

  Parameters                                                                                                              *ROS1*-rearranged NSCLC (*N* = 53)
  ----------------------------------------------------------------------------------------------------------------------- ------------------------------------
  Deaths, *n* (%)                                                                                                         26 (49)
  Median duration of follow-up[^a^](#tblfn11){ref-type="table-fn"}, months (95% CI)[^b^](#tblfn12){ref-type="table-fn"}   62.6 (58.2--66.6)
  Median OS, months (95% CI)[^b^](#tblfn12){ref-type="table-fn"}                                                          51.4 (29.3--NR)
  Survival probability, % (95% CI)[^c^](#tblfn13){ref-type="table-fn"}                                                    
   6 months                                                                                                               91 (79--96)
   12 months                                                                                                              79 (65--88)
   24 months                                                                                                              67 (52--78)
   36 months                                                                                                              53 (38--66)
   48 months                                                                                                              51 (36--64)

Estimated using reverse Kaplan--Meier method.

Based on the Brookmeyer and Crowley method.

Calculated using normal approximation to the log transformed cumulative hazard function.

CI, confidence interval; NSCLC, non-small-cell lung cancer; NR, not reached; OS, overall survival.

We previously identified the ROS1 fusion partner in the tumors of 30 patients enrolled in the ROS1 expansion cohort \[[@mdz131-B5]\]. Among the 25 cases with detectable *ROS1* rearrangements, we identified seven different fusion partners, including CD74 (in 11 tumors), EZR and SDC4 (each in 4 tumors), SLC34A2 (in 3 tumors), and LIMA1, MSN, and TPM3 (each in 1 tumor). We previously showed that the fusion partner does not appear to impact response rate or DOR with crizotinib \[[@mdz131-B5]\]. To determine whether the fusion partner may impact survival, we evaluated OS according to ROS1 fusion partner. There was no apparent correlation between the specific *ROS1* rearrangement and OS, with a wide range of survival durations seen within each class of *ROS1* rearrangement (Figure [2](#mdz131-F2){ref-type="fig"}). These findings suggest that crizotinib is active in *ROS1*-rearranged advanced NSCLC, regardless of the exact ROS1 fusion partner.

![Overall survival and ROS1 fusion partners. Shown is overall survival (OS) for the 30 patients who underwent testing for ROS1 fusion partners. Patients are grouped according to ROS1 fusion partner, shown on the left. Asterisks indicate censored patients. One patient was identified as positive for both *ROS1* and *ALK* rearrangement by FISH testing, but next-generation sequencing (NGS) revealed only an EML4-ALK fusion and no *ROS1* rearrangement (triangle). One patient was identified as positive for *ROS1* rearrangement by FISH testing, but had an atypical FISH pattern, and NGS subsequently revealed normal, non-rearranged *ROS1* (circle).](mdz131f2){#mdz131-F2}

Safety
------

At the time of data cutoff, 12 (23%) patients remained on treatment and 41 (77%) patients had permanently discontinued. Reasons for permanent treatment discontinuation included progressive disease (45%), withdrawal of consent (11%), clinical progression (15%), switch to commercially available crizotinib (4%), and death (2%). Median duration of treatment was 22.4 months (95% CI, 15.0--35.9) compared with 14.8 months (range, 0.5--41.9) reported previously \[[@mdz131-B5]\]. All 53 patients experienced at least one treatment-related AE (TRAE). The majority of TRAEs were grade 1 or 2 in severity, and the most common (≥30%) were vision disorder (87%), nausea (51%), edema (47%), diarrhea (45%), vomiting (38%), elevated transaminases (36%), and constipation (34%) (Table [4](#mdz131-T4){ref-type="table"}). The most common (≥3%) grade 3 TRAEs were hypophosphatemia (15%), neutropenia (9%), elevated transaminases (4%), and vomiting (4%). There were no grade 4 or 5 TRAEs. No TRAEs were associated with permanent discontinuation of treatment.

###### 

Treatment-related AEs reported in ≥10% of patients

  Event                                                        *ROS1*-rearranged NSCLC (*N* = 53)   
  ------------------------------------------------------------ ------------------------------------ ---------
  Any AE[^a^](#tblfn15){ref-type="table-fn"}                   53 (100)                             19 (36)
  Vision disorder[^b^](#tblfn16){ref-type="table-fn"}          46 (87)                              0 (0)
  Nausea                                                       27 (51)                              1 (2)
  Edema[^b^](#tblfn16){ref-type="table-fn"}                    25 (47)                              0 (0)
  Diarrhea                                                     24 (45)                              0 (0)
  Vomiting                                                     20 (38)                              2 (4)
  Elevated transaminases[^b^](#tblfn16){ref-type="table-fn"}   19 (36)                              2 (4)
  Constipation                                                 18 (34)                              0 (0)
  Bradycardia[^b^](#tblfn16){ref-type="table-fn"}              11 (21)                              0 (0)
  Fatigue                                                      11 (21)                              0 (0)
  Dizziness[^b^](#tblfn16){ref-type="table-fn"}                10 (19)                              0 (0)
  Dysgeusia                                                    10 (19)                              0 (0)
  Hypophosphatemia                                             9 (17)                               8 (15)
  Decreased appetite                                           8 (15)                               1 (2)
  Neutropenia[^b^](#tblfn16){ref-type="table-fn"}              8 (15)                               5 (9)
  Rash                                                         7 (13)                               0 (0)

Independent of the 10% cut-off used in this table; no grade 4 or 5 treatment-related AEs were reported.

Clustered term comprising AEs that represent similar clinical symptoms/syndromes.

AE, adverse event; NSCLC, non-small-cell lung cancer.

Discussion
==========

The initial results of the PROFILE 1001 ROS1 expansion cohort established crizotinib as a standard therapy for *ROS1*-rearranged advanced NSCLC. In this updated analysis, after an additional \>3-year follow-up, we have confirmed the marked efficacy of crizotinib in *ROS1*-rearranged advanced NSCLC and showed that crizotinib treatment is associated with prolonged survival, with a median OS of 51.4 months and an OS rate of 51% at 48 months. In addition, our findings support the favorable safety profile of crizotinib, even with long-term treatment. No unexpected safety signals were identified in this updated analysis, and the safety profile was similar to previous reports in patients with *ALK*- or *ROS1*-rearranged NSCLC \[[@mdz131-B5]\].

Overall, the efficacy of crizotinib in this updated analysis was highly consistent with our initial results on 50 patients with *ROS1*-rearranged advanced NSCLC \[[@mdz131-B5]\]. In the original analysis after a median follow-up of 16.4 months, ORR was 72% (95% CI, 58% to 84%), and median PFS was 19.2 months (95% CI, 14.4 to NR), with 50% of patients still in follow-up for progression \[[@mdz131-B5]\]. Similarly, in this updated analysis, after a median follow-up of 62.6 months, ORR and median PFS were nearly identical at 72% (95% CI, 58% to 83%) and 19.3 months (95% CI, 15.2--39.1), respectively, with 15% of patients still in follow-up for progression. Of note, DOR was longer in the updated analysis, with median DOR of 24.7 months (95% CI, 15.2--45.3), compared with 17.6 months in the initial study (95% CI, 14.5 to NR) \[[@mdz131-B5]\].

To date, the clinical activity of crizotinib has been examined in two other prospective studies of *ROS1*-rearranged advanced NSCLC. In a larger phase II study of crizotinib conducted in East Asia, the ORR among 127 patients was 72% (95% CI, 63% to 79%), median PFS was 15.9 months (95% CI, 12.9--24.0), and median DOR was 19.7 months (95% CI, 14.1 to NR) \[[@mdz131-B8]\], similar to the results of this updated analysis of PROFILE 1001. In a smaller phase II study conducted in France (AcSé), the ORR among 37 patients with *ROS1*-rearranged advanced NSCLC was also high at 68% (95% CI, 50% to 82%). While median PFS in this study was relatively short \[5.5 months (95% CI, 4.6--9.1)\], the follow-up period for PFS was not reported and the maturity of these data were not confirmed \[[@mdz131-B9]\]. The variations in PFS among these three trials may be influenced by the relatively small trial populations. Baseline differences in the study populations may have also contributed to these variations; notably, 25% of patients in the AcSé trial had an ECOG PS of 2 \[[@mdz131-B9]\].

This update to PROFILE 1001 reports for the first time mature survival data in *ROS1*-rearranged advanced NSCLC. In this mostly pretreated population of ROS1-positive patients, OS from the time of crizotinib initiation was remarkably prolonged with a median OS of 51.4 months; this was independent of the exact *ROS1* rearrangement. The prolonged survival observed in this updated analysis is reminiscent of that reported in the first-line study of crizotinib versus standard chemotherapy in *ALK*-rearranged advanced NSCLC (PROFILE 1014). Here, median OS was not reached in the crizotinib group (95% CI, 45.8 months to NR), but the probability of survival at 4 years was 56.6% \[[@mdz131-B10]\], similar to the 51% rate seen in this updated analysis. Thus, in two distinct subtypes of advanced NSCLC---*ALK*-rearranged and *ROS1*-rearranged---crizotinib is associated with prolonged survival and median survival times exceed four years.

In addition to crizotinib, numerous other TKIs with ROS1 activity have been investigated in *ROS1*-rearranged advanced NSCLC. For example, the second-generation ALK inhibitor ceritinib was tested in 32 Korean patients with *ROS1*-rearranged NSCLC, of whom, 30 were crizotinib-naive. Similar to PROFILE 1001, ORR was 67% (95% CI, 48% to 81%) and median PFS was 19.3 months (95% CI, 1--37) in crizotinib-naive patients \[[@mdz131-B11]\]. Of note, after a median follow-up of 14 months, median OS was only 24 months (95% CI, 5--43) in all patients, with a 12-month survival probability of 56%. The ROS1/NTRK/ALK inhibitor entrectinib has also demonstrated potent clinical activity in crizotinib-naive *ROS1*-rearranged NSCLC \[[@mdz131-B12]\]. Among 53 ROS1-positive patients pooled from 3 separate trials of entrectinib, ORR was 77% (95% CI, 64% to 88%) and median PFS was 19.0 months (95% CI, 12.2--36.6). However, OS data from this pooled analysis are not yet mature. Other TKIs with promising clinical activity in *ROS1*-rearranged NSCLC include lorlatinib, repotrectinib, and DS-6051b \[[@mdz131-B13]\]. While efficacy data with other ROS1 TKIs are still emerging, our findings show that treatment with crizotinib is associated with impressive OS in *ROS1*-rearranged advanced NSCLC.

In conclusion, this study provides a new benchmark for OS in patients with *ROS1*-rearranged advanced NSCLC and supports the continued use of crizotinib in the treatment of these patients.
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